Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Eastwood Bio-Medical Canada's Enterprise Value is C$68.26 Mil.
Eastwood Bio-Medical Canada's Free Cash Flow for the trailing twelve months (TTM) ended in Apr. 2026 was C$0.00 Mil. Therefore, Eastwood Bio-Medical Canada's EV-to-FCF for today is 22,752.00.
The historical rank and industry rank for Eastwood Bio-Medical Canada's EV-to-FCF or its related term are showing as below:
TSXV:EBM'
s EV-to-FCF Range Over the Past 10 Years
Min: -22393.7 Med: -732.92 Max: 22752.05
Current: 22752
During the past 13 years, the highest EV-to-FCF of Eastwood Bio-Medical Canada was 22752.05. The lowest was -22393.70. And the median was -732.92.
TSXV:EBM's EV-to-FCF is ranked worse than 99.71% of 343
companies
in the Biotechnology industry
Industry Median: 14.79
vs TSXV:EBM: 22752.00
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Eastwood Bio-Medical Canada's PE Ratio (TTM) for today is calculated as:
Eastwood Bio-Medical Canada's share price for today is C$0.99.
Eastwood Bio-Medical Canada's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.030.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Eastwood Bio-Medical Canada EV-to-FCF Related Terms
Eastwood Bio-Medical Canada EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSXV:EBM vs VRTX, REGN, RVMD: EV-to-FCF Comparison
For the Biotechnology subindustry, Eastwood Bio-Medical Canada's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eastwood Bio-Medical Canada EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Eastwood Bio-Medical Canada's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Eastwood Bio-Medical Canada's EV-to-FCF falls into.
Eastwood Bio-Medical Canada's current Enterprise Value is C$68.26 Mil.
Eastwood Bio-Medical Canada's Free Cash Flow for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eastwood Bio-Medical Canada (TSXV:EBM) has a EV-to-FCF of 22,752.00 as of Jul. 27, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Eastwood Bio-Medical Canada and its competitors. According to the industry distribution chart, Eastwood Bio-Medical Canada ranks #342 out of 343 companies in the Biotechnology industry, placing it in the top 99.7%.
Is Eastwood Bio-Medical Canada's EV-to-FCF too high?
Eastwood Bio-Medical Canada's current EV-to-FCF is 22,752.00. The Biotechnology industry median EV-to-FCF is 14.79. Eastwood Bio-Medical Canada's value of 22,752.00 is 153733.7% above this industry median. Based on the distribution chart, Eastwood Bio-Medical Canada ranks #342 out of 343 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Eastwood Bio-Medical Canada has a GF Score™ of 25/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Eastwood Bio-Medical Canada's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Eastwood Bio-Medical Canada ranks #342 out of 343 companies for EV-to-FCF. This places Eastwood Bio-Medical Canada in the lower half of its industry. The industry median EV-to-FCF is 14.79. Eastwood Bio-Medical Canada's value of 22,752.00 is 153733.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 14.79, based on 343 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eastwood Bio-Medical Canada's current EV-to-FCF of 22,752.00 is 153733.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Eastwood Bio-Medical Canada and its competitors. For the Biotechnology industry, the median EV-to-FCF is 14.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eastwood Bio-Medical Canada's current EV-to-FCF is 22,752.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eastwood Bio-Medical Canada stock overvalued right now?
Based on GuruFocus' analysis, Eastwood Bio-Medical Canada (TSXV:EBM) is currently considered Significantly Overvalued. The stock's GF Value™ is C$0.53, compared to a current price of C$0.99 — trading 86.8% above its estimated fair value. The current EV-to-FCF is 22,752.00 and 153733.7% above the Biotechnology industry median of 14.79. Eastwood Bio-Medical Canada's overall GF Score™ is 25/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Eastwood Bio-Medical Canada (TSXV:EBM), the current EV-to-FCF is 22,752.00 as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eastwood Bio-Medical Canada (TSXV:EBM) Overvalued in 2026?
Based on GuruFocus' analysis, Eastwood Bio-Medical Canada stock appears to be overvalued.
The current stock price of C$0.99 is trading 86.8% above its estimated GF Value™ of C$0.53.
GuruFocus considers Eastwood Bio-Medical Canada to be Significantly Overvalued.
Key valuation signals for TSXV:EBM:
EV-to-FCF: 22,752.00
GF Value™: C$0.53 vs. price of C$0.99 (86.8% above fair value)
Industry Position: 153733.7% above the Biotechnology median (#342 of 343)
No single metric tells the full story. See the TSXV:EBM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eastwood Bio-Medical Canada Inc is a Canadian company engaged in the development and commercialization of safe and effective treatment for non-insulin dependent diabetes mellitus. The company is engaged in natural health supplement distribution company. It has its geographic presence in U.S., Canada and Asia. The company generates maximum revenue from Asia.
25GF Score
Get the complete analysis for TSXV:EBM
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSXV:EBM has been successfully added to your 
